Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging

"Currently in France is running a trial with Pioglitazone . Although the subject matter of the article is not about the FA, get more information about this drug is interesting."

OPEN ACCES

PLoS ONE 5(4): e10405. doi:10.1371/journal.pone.0010405

Eric M. Blalock^1#, Jeremiah T. Phelps^1#, Tristano Pancani¹, James L. Searcy¹, Katie L. Anderson¹, John C. Gant¹, Jelena Popovic¹, Margarita G. Avdiushko², Don A. Cohen², Kuey-Chu Chen¹, Nada M. Porter¹, Olivier Thibault^1*

1 Department of Molecular and Biomedical Pharmacology, University of Kentucky Medical Center, Lexington, Kentucky, United States of America, 2 Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington, Kentucky, United States of America

Abstract

Thiazolidinediones (TZDs) activate peroxisome proliferator-activated receptor gamma (PPARγ) and are used clinically to help restore peripheral insulin sensitivity in Type 2 diabetes (T2DM). Interestingly, long-term treatment of mouse models of Alzheimer's disease (AD) with TZDs also has been shown to reduce several well-established brain biomarkers of AD including inflammation, oxidative stress and Aβ accumulation. While TZD's actions in AD models help to elucidate the mechanisms underlying their potentially beneficial effects in AD patients, little is known about the functional consequences of TZDs in animal models of normal aging. Because aging is a common risk factor for both AD and T2DM, we investigated whether the TZD, pioglitazone could alter brain aging under non-pathological conditions.

FULL TEXT PDF

Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor

European Journal of Clinical Investigation, Early View (Articles online in advance of print), Published Online: 28 Apr 2010
BRIEF COMMUNICATION

Brigitte Sturm*, Melissa Helminger*, Hannes Steinkellner*, Mohammad Mehdi Heidari*,†, Hans Goldenberg* and Barbara Scheiber-Mojdehkar*
*Medical University of Vienna, Vienna, Austria , † Yazd University, Yazd, Iran

KEYWORDS: Carbamylated erythropoietin • erythropoietin receptor • frataxin • Friedreich's ataxia • nonerythropoietic erythropoietin • recombinant human erythropoietin